📢 𝐉𝐔𝐒𝐓 𝐈𝐍: $Viking Therap(VKTX.US) Viking Therapeutics Launches Phase 1 Trial for New Weight-Loss Drug VK3019
👉 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:➤ 𝐕𝐢𝐤𝐢𝐧𝐠 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 initiated a 𝐏𝐡𝐚𝐬𝐞 𝟏 trial of weight-loss candidate VK3019.➤ VK3019 is a 𝐝𝐮𝐚𝐥 𝐚𝐦𝐲𝐥𝐢𝐧 and 𝐜𝐚𝐥𝐜𝐢𝐭𝐨𝐧𝐢𝐧 receptor agonist (DACRA).➤ Trial follows 𝐅𝐃𝐀 clearance of VK3019's Investigational New Drug application.➤ Study will evaluate 𝐬𝐚𝐟𝐞𝐭𝐲, 𝐭𝐨𝐥𝐞𝐫𝐚𝐛𝐢𝐥𝐢𝐭𝐲, and pharmacokinetics in adults with BMI ≥ 30.➤ Exploratory assessments include changes in 𝐛𝐨𝐝𝐲 𝐰𝐞𝐢𝐠𝐡𝐭 after a single dose.➤ Preclinical data showed up to 𝟖% 𝐛𝐨𝐝𝐲-𝐰𝐞𝐢𝐠𝐡𝐭 reduction within 72 hours in animal studies.➤ Viking is also conducting 𝐏𝐡𝐚𝐬𝐞 𝟑 VANQUISH trials for obesity drug VK2735.➤ Company plans to launch a 𝐏𝐡𝐚𝐬𝐞 𝟑 trial of oral VK2735 later in 2026.👉 𝐖𝐡𝐲 𝐈𝐭 𝐌𝐚𝐭𝐭𝐞𝐫𝐬:➤ VK3019 expands Viking's pipeline in the rapidly growing 𝐨𝐛𝐞𝐬𝐢𝐭𝐲 treatment market.➤ DACRA therapies could complement 𝐆𝐋𝐏-𝟏 and GLP-1/GIP weight-loss medicines.➤ Success could provide additional 𝐥𝐨𝐧𝐠-𝐭𝐞𝐫𝐦 𝐰𝐞𝐢𝐠𝐡𝐭-𝐦𝐚𝐧𝐚𝐠𝐞𝐦𝐞𝐧𝐭 options for patients.👉 𝐄𝐱𝐩𝐞𝐫𝐭 𝐒𝐭𝐚𝐭𝐞𝐦𝐞𝐧𝐭:➤ "The initiation of VK3019's Phase 1 study marks an important expansion of our portfolio of novel therapies designed to optimize the weight loss journey for patients and their physicians." — 𝐁𝐫𝐢𝐚𝐧 𝐋𝐢𝐚𝐧, Ph.D., Chief Executive Officer of Viking Therapeutics.➤ "Therapies that target amylin and calcitonin receptors may potentially be used alone or in combination with GLP-1 or dual GLP-1/GIP agonists to improve the induction of weight loss as well as for longer-term weight management." — 𝐁𝐫𝐢𝐚𝐧 𝐋𝐢𝐚𝐧.➤ "Broadening the potential treatment options is crucial to meeting the diverse needs of individuals seeking safe and sustainable weight loss." — 𝐁𝐫𝐢𝐚𝐧 𝐋𝐢𝐚𝐧.25.4800.00% ( 0.000 )
Closed: Jul 29, 16:00:00 (EDT)GLOBAL PARTNERS LP 9.50% FIXED RATE CUM RED PERP SER B (GLP-B)
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- 25.480
- Volume
- 0
- Turnover
- 0
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- 25.630
- Volume Ratio
- 0.00
- Turnover Ratio
- --
- 52wk Low
- 23.717
- Float Mkt Cap
- --
- Market CapUSD
- --
- P/ETTM
- --
- P/EDynamic
- --
- P/EStatic
- --
- EPSTTM
- --
- EPSDynamic
- --
- EPSStatic
- --
- BVPS
- --
- P/B
- --
- Circulating Supply
- 0.00
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 0.00
- Min lot size
- 1
- Currency
- USD
Posts
View more- T
GLP 1 demand is exploding because everyone wants the easy button, quick fix, no effort, no discipline
I dropped 50 pounds in 5 monthsNo drugsJust sleep, clean diet, resistance training, consistencyThere is no secret, just boring execution every single dayIf I can do it, anyone canThis is not a flex, this is proof that discipline still works - MMarina Bay
Traded Value$Hims & Hers Health(HIMS.US) holds leading scale in US direct-to-consumer personalized telehealth (~2x the size of many #2 players).
Core moat includes data flywheel (labs with 130+ biomarkers), high customer trust/brand, low churn via subscriptions, and supplier networks. Competitors include Ro/Roman, traditional telehealth, and branded pharma direct channels.
Threats from GLP-1 price competition and compounding regulations are being actively mitigated via branded pivots and diversification. Market share continues expanding in core categories.
@Bridge Buzz SG
NewDiscussionZones

